Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF) analyst actions
Rating and price-target actions on CANF in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CANF overview →
1 measured CANF analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol | Press release | -6.90% | -6.90% |
Keep exploring
More CANF: earnings → · SEC filings → · CANF overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | 279 | -0.52% | 36% |
| CORREVIO PHARMA CORP ORDINARY SHARES (CORV) | 279 | 0.00% | 44% |
| AtriCure, Inc. (ATRC) | 276 | +0.04% | 51% |
| Coherus Oncology, Inc. (CHRS) | 276 | +0.21% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.